Equities research analysts expect that Orthopediatrics Corp (NASDAQ:KIDS) will report $19.82 million in sales for the current quarter, according to Zacks. Three analysts have provided estimates for Orthopediatrics’ earnings. The lowest sales estimate is $19.65 million and the highest is $20.10 million. Orthopediatrics reported sales of $15.82 million in the same quarter last year, which would suggest a positive year over year growth rate of 25.3%. The business is scheduled to issue its next earnings results on Wednesday, October 30th.

On average, analysts expect that Orthopediatrics will report full-year sales of $71.33 million for the current fiscal year, with estimates ranging from $71.29 million to $71.40 million. For the next financial year, analysts anticipate that the firm will report sales of $87.46 million, with estimates ranging from $86.59 million to $88.10 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that cover Orthopediatrics.

Orthopediatrics (NASDAQ:KIDS) last released its earnings results on Wednesday, August 7th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.05). The company had revenue of $18.20 million for the quarter, compared to analyst estimates of $18.44 million. Orthopediatrics had a negative return on equity of 12.92% and a negative net margin of 15.77%. The business’s revenue for the quarter was up 20.5% compared to the same quarter last year. During the same period last year, the company posted ($0.21) earnings per share.

Several analysts have recently issued reports on the company. BidaskClub lowered Orthopediatrics from a “buy” rating to a “hold” rating in a report on Friday, September 27th. Zacks Investment Research raised Orthopediatrics from a “hold” rating to a “buy” rating and set a $37.00 target price on the stock in a report on Thursday, October 10th. Finally, ValuEngine lowered Orthopediatrics from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $44.50.

KIDS opened at $36.18 on Tuesday. The firm has a market cap of $552.91 million, a P/E ratio of -37.69 and a beta of 0.21. Orthopediatrics has a 52-week low of $25.11 and a 52-week high of $47.82. The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.75 and a current ratio of 2.53. The business’s fifty day moving average is $35.52 and its 200-day moving average is $37.03.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Envestnet Asset Management Inc. acquired a new stake in shares of Orthopediatrics during the 3rd quarter worth $238,000. Riverbridge Partners LLC boosted its stake in Orthopediatrics by 41.3% in the third quarter. Riverbridge Partners LLC now owns 513,070 shares of the company’s stock valued at $18,091,000 after buying an additional 149,855 shares in the last quarter. Roubaix Capital LLC boosted its stake in Orthopediatrics by 35.5% in the third quarter. Roubaix Capital LLC now owns 121,501 shares of the company’s stock valued at $4,284,000 after buying an additional 31,845 shares in the last quarter. Prospect Capital Advisors LLC boosted its stake in Orthopediatrics by 11.6% in the second quarter. Prospect Capital Advisors LLC now owns 230,100 shares of the company’s stock valued at $8,974,000 after buying an additional 24,000 shares in the last quarter. Finally, Scholtz & Company LLC boosted its stake in Orthopediatrics by 17.3% in the second quarter. Scholtz & Company LLC now owns 6,675 shares of the company’s stock valued at $260,000 after buying an additional 985 shares in the last quarter. 49.38% of the stock is currently owned by institutional investors.

Orthopediatrics Company Profile

OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company's products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail products, PediLoc tibia products, anterior cruciate ligament reconstruction systems, locking cannulated blades, locking proximal femurs, RESPONSE Spine systems, Bandloc, and Pediguard.

Recommended Story: Why do companies issue convertible shares?

Get a free copy of the Zacks research report on Orthopediatrics (KIDS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Orthopediatrics (NASDAQ:KIDS)

Receive News & Ratings for Orthopediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthopediatrics and related companies with MarketBeat.com's FREE daily email newsletter.